APA aipamena

Cebollero, A., Puértolas, T., Pajares, I., Calera, L., & Antón, A. (2016). Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Mol Clin Oncol.

Chicago Style aipamena

Cebollero, Ana, Teresa Puértolas, Isabel Pajares, Lourdes Calera, and Antonio Antón. "Comparative Safety of BRAF and MEK Inhibitors (vemurafenib, Dabrafenib and Trametinib) in First-line Therapy for BRAF-mutated Metastatic Melanoma." Mol Clin Oncol 2016.

MLA aipamena

Cebollero, Ana, et al. "Comparative Safety of BRAF and MEK Inhibitors (vemurafenib, Dabrafenib and Trametinib) in First-line Therapy for BRAF-mutated Metastatic Melanoma." Mol Clin Oncol 2016.